Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Ángel Crespo López, Robert F. Grover, Michael Brockway et al.|Critical Care Medicine|2004Cited by 921
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shockRobert F. Grover, Jean‐Louis Vincent, David I. Watson et al.|Critical Care Medicine|1999Cited by 200
Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*Jan Bakker, Jukka Takala, Robert F. Grover et al.|Critical Care Medicine|2004Cited by 196